Anticoagulant fusion proteins and uses thereof
AssigneeBioxodes
InventorsStéphanie Demoulin, Edmond Godfroid, Michel Guyaux, Joël Tassignon
Life of this patent
Estimating the term…
Abstract
Disclosed is a fusion protein including an Ixodes ricinus salivary gland polypeptide. In particular, it relates to a fusion protein including at least one Ixodes ricinus salivary gland polypeptide, at least one serum albumin polypeptide and at least one linker peptide. Also disclosed is the use of such a fusion protein for preventing or treating thrombus formation and/or thrombus growth, as well as pharmaceutical compositions, medicaments and methods including such a fusion protein.
Claims7
A fusion protein comprising (i) at least one Ixodes ricinus salivary gland (IrCPI) polypeptide, having an amino acid sequence at least 95% identical to SEQ ID NO:
- 1, (ii) at least one human serum albumin polypeptide and (iii) at least one peptide linker, wherein the fusion protein has an increased circulatory half-life compared to an unfused IrCPI polypeptide, wherein said at least one peptide linker is a Pro-rich linker selected from a group consisting of (AP)n and P(AP)n linker, and wherein “n” is a number from 5 to 15.
A pharmaceutical composition or a medicament comprising a fusion protein comprising (i) at least one Ixodes ricinus salivary gland (IrCPI) polypeptide, having an amino sequence at least 95% identical to SEQ ID NO:
- 1, (ii) at least one human serum albumin polypeptide and (iii) at least one peptide linker, wherein the fusion protein has an increased circulatory half-life compared to an unfused IrCPI polypeptide, and at least one pharmaceutically acceptable excipient, wherein said at least one peptide linker is a Pro-rich linker selected from a group consisting of (AP)n and P(AP)n linker, and wherein “n” is a number from 5 to 15.
Dependencies are inferred from the claim text.